197 related articles for article (PubMed ID: 25663076)
1. Liposomal delivery of dexamethasone attenuates prostate cancer bone metastatic tumor growth in vivo.
Kroon J; Buijs JT; van der Horst G; Cheung H; van der Mark M; van Bloois L; Rizzo LY; Lammers T; Pelger RC; Storm G; van der Pluijm G; Metselaar JM
Prostate; 2015 Jun; 75(8):815-24. PubMed ID: 25663076
[TBL] [Abstract][Full Text] [Related]
2. RGD peptide conjugated liposomal drug delivery system for enhance therapeutic efficacy in treating bone metastasis from prostate cancer.
Wang F; Chen L; Zhang R; Chen Z; Zhu L
J Control Release; 2014 Dec; 196():222-33. PubMed ID: 25456829
[TBL] [Abstract][Full Text] [Related]
3. Liposomal dexamethasone inhibits tumor growth in an advanced human-mouse hybrid model of multiple myeloma.
Deshantri AK; Fens MH; Ruiter RWJ; Metselaar JM; Storm G; van Bloois L; Varela-Moreira A; Mandhane SN; Mutis T; Martens ACM; Groen RWJ; Schiffelers RM
J Control Release; 2019 Feb; 296():232-240. PubMed ID: 30682443
[TBL] [Abstract][Full Text] [Related]
4. An exploratory first-in-man study to investigate the pharmacokinetics and safety of liposomal dexamethasone at a 2- and 1-week interval in patients with metastatic castration resistant prostate cancer.
Vrouwe JPM; Kamerling IMC; van Esdonk MJ; Metselaar JM; Stuurman FE; van der Pluijm G; Burggraaf J; Osanto S
Pharmacol Res Perspect; 2021 Oct; 9(5):e00845. PubMed ID: 34414692
[TBL] [Abstract][Full Text] [Related]
5. Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment.
Magnusson LU; Hagberg Thulin M; Plas P; Olsson A; Damber JE; Welén K
Prostate; 2016 Mar; 76(4):383-93. PubMed ID: 26660725
[TBL] [Abstract][Full Text] [Related]
6. Targeting of α(v)-integrins in stem/progenitor cells and supportive microenvironment impairs bone metastasis in human prostate cancer.
van der Horst G; van den Hoogen C; Buijs JT; Cheung H; Bloys H; Pelger RC; Lorenzon G; Heckmann B; Feyen J; Pujuguet P; Blanque R; Clément-Lacroix P; van der Pluijm G
Neoplasia; 2011 Jun; 13(6):516-25. PubMed ID: 21677875
[TBL] [Abstract][Full Text] [Related]
7. Liposomal nanomedicines in the treatment of prostate cancer.
Kroon J; Metselaar JM; Storm G; van der Pluijm G
Cancer Treat Rev; 2014 May; 40(4):578-84. PubMed ID: 24216226
[TBL] [Abstract][Full Text] [Related]
8. Liposomes promote pulmonary glucocorticoid delivery.
Suntres ZE; Shek PN
J Drug Target; 1998; 6(3):175-82. PubMed ID: 9888303
[TBL] [Abstract][Full Text] [Related]
9. Dual-ligand modified liposomes provide effective local targeted delivery of lung-cancer drug by antibody and tumor lineage-homing cell-penetrating peptide.
Lin C; Zhang X; Chen H; Bian Z; Zhang G; Riaz MK; Tyagi D; Lin G; Zhang Y; Wang J; Lu A; Yang Z
Drug Deliv; 2018 Nov; 25(1):256-266. PubMed ID: 29334814
[TBL] [Abstract][Full Text] [Related]
10. Anti-metastatic effects of liposomal gemcitabine in a human orthotopic LNCaP prostate cancer xenograft model.
Jantscheff P; Ziroli V; Esser N; Graeser R; Kluth J; Sukolinskaya A; Taylor LA; Unger C; Massing U
Clin Exp Metastasis; 2009; 26(8):981-92. PubMed ID: 19784785
[TBL] [Abstract][Full Text] [Related]
11. Antitumor efficacy of dexamethasone-loaded core-crosslinked polymeric micelles.
Coimbra M; Rijcken CJ; Stigter M; Hennink WE; Storm G; Schiffelers RM
J Control Release; 2012 Nov; 163(3):361-7. PubMed ID: 23041274
[TBL] [Abstract][Full Text] [Related]
12. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
[TBL] [Abstract][Full Text] [Related]
13. Agents targeting prostate cancer bone metastasis.
Mohammad KS; Fournier PG; Guise TA; Chirgwin JM
Anticancer Agents Med Chem; 2009 Dec; 9(10):1079-88. PubMed ID: 19719455
[TBL] [Abstract][Full Text] [Related]
14. Synergistic dual-modified liposome improves targeting and therapeutic efficacy of bone metastasis from breast cancer.
Ke X; Lin W; Li X; Wang H; Xiao X; Guo Z
Drug Deliv; 2017 Nov; 24(1):1680-1689. PubMed ID: 29092646
[TBL] [Abstract][Full Text] [Related]
15. Dual PI3 K/mTOR inhibition reduces prostate cancer bone engraftment altering tumor-induced bone remodeling.
Mancini A; Colapietro A; Pompili S; Del Fattore A; Delle Monache S; Biordi LA; Angelucci A; Mattei V; Liang C; Gravina GL; Festuccia C
Tumour Biol; 2018 Apr; 40(4):1010428318771773. PubMed ID: 29687745
[TBL] [Abstract][Full Text] [Related]
16. Enhancing solid tumor therapy with sequential delivery of dexamethasone and docetaxel engineered in a single carrier to overcome stromal resistance to drug delivery.
Zhang L; Su H; Liu Y; Pang N; Li J; Qi XR
J Control Release; 2019 Jan; 294():1-16. PubMed ID: 30527754
[TBL] [Abstract][Full Text] [Related]
17. Plumbagin attenuates cancer cell growth and osteoclast formation in the bone microenvironment of mice.
Yan W; Wang TY; Fan QM; Du L; Xu JK; Zhai ZJ; Li HW; Tang TT
Acta Pharmacol Sin; 2014 Jan; 35(1):124-34. PubMed ID: 24384612
[TBL] [Abstract][Full Text] [Related]
18. Noninvasive Imaging of Liposomal Delivery of Superparamagnetic Iron Oxide Nanoparticles to Orthotopic Human Breast Tumor in Mice.
Kato Y; Zhu W; Backer MV; Neoh CC; Hapuarachchige S; Sarkar SK; Backer JM; Artemov D
Pharm Res; 2015 Nov; 32(11):3746-3755. PubMed ID: 26078000
[TBL] [Abstract][Full Text] [Related]
19. Novel drug delivery liposomes targeted with a fully human anti-VEGF165 monoclonal antibody show superior antitumor efficacy in vivo.
Shi C; Cao H; He W; Gao F; Liu Y; Yin L
Biomed Pharmacother; 2015 Jul; 73():48-57. PubMed ID: 26211582
[TBL] [Abstract][Full Text] [Related]
20. Liposomal Carrier Conjugated to APP-Derived Peptide for Brain Cancer Treatment.
Gabay M; Weizman A; Zeineh N; Kahana M; Obeid F; Allon N; Gavish M
Cell Mol Neurobiol; 2021 Jul; 41(5):1019-1029. PubMed ID: 33025416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
